Concomitant use of clopidogrel and statins and risk of major adverse cardiovascular events following coronary stent implantation
British Journal of Clinical Pharmacology, 04/24/2012Schmidt M et al.
Clopidogrel and CYP3A4–metabolizing statin use were each associated with a substantially reduced rate of major adverse cardiovascular events (MACE) within 12 months after coronary stent implantation. Although authors observed an interaction between use of clopidogrel and statins, statin use vs. nonuse was not associated with an increased rate of MACE in patients using clopidogrel after coronary stent implantation.
Authors conducted this population–based cohort study in Western Denmark (population: 3 million) using medical databases.
They identified all 13,001 patients with coronary stent implantation between 2002 and 2005 and their comorbidities.
During 12–month follow–up, they tracked the use of clopidogrel and CYP3A4–metabolizing statins and the rate of MACE.
They used Cox regression to compute hazard ratios (HRs) controlling for potential confounders.
The rate of MACE per 1000 person years was 104 for concomitant clopidogrel and statin use, 130 for clopidogrel without statin use, 108 for statin without clopidogrel use, and 446 for no use of either drug.
The adjusted HR comparing clopidogrel use with non–use was 0.68 (95% confidence interval (CI): 0.58–0.79) among statin users and 0.34 (95% CI: 0.29–0.40) among statin non–users, yielding an interaction effect (i.e., relative rate increase) of 1.97 (95% CI: 1.59–2.44).
The adjusted HR for MACE comparing statin use with non–use was 0.97 (95% CI: 0.83–1.13) among clopidogrel users and 0.49 (95% CI: 0.42–0.57) among clopidogrel non–users.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.